-
1
-
-
4344694453
-
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System
-
PID: 15254054
-
Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22(14):2865–2872
-
(2004)
J Clin Oncol
, vol.22
, Issue.14
, pp. 2865-2872
-
-
Barnholtz-Sloan, J.S.1
Sloan, A.E.2
Davis, F.G.3
Vigneau, F.D.4
Lai, P.5
Sawaya, R.E.6
-
2
-
-
84867772278
-
Melanoma brain metastases: Overview of current management and emerging targeted therapies
-
PID: 23082737, COI: 1:CAS:528:DC%2BC38XhsFekur3K
-
Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, Wong ET (2012) Melanoma brain metastases: overview of current management and emerging targeted therapies. Expert Rev Neurother 12(10):1207–1215
-
(2012)
Expert Rev Neurother
, vol.12
, Issue.10
, pp. 1207-1215
-
-
Fonkem, E.1
Uhlmann, E.J.2
Floyd, S.R.3
Mahadevan, A.4
Kasper, E.5
Eton, O.6
Wong, E.T.7
-
3
-
-
84857034419
-
Brain metastases: Pathobiology and emerging targeted therapies
-
PID: 22212630, COI: 1:CAS:528:DC%2BC38XpslyrsA%3D%3D
-
Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123(2):205–222
-
(2012)
Acta Neuropathol
, vol.123
, Issue.2
, pp. 205-222
-
-
Preusser, M.1
Capper, D.2
Ilhan-Mutlu, A.3
Berghoff, A.S.4
Birner, P.5
Bartsch, R.6
Marosi, C.7
Zielinski, C.8
Mehta, M.P.9
Winkler, F.10
Wick, W.11
von Deimling, A.12
-
4
-
-
79953781233
-
Prognostic factors for survival in melanoma patients with brain metastases
-
PID: 20960525
-
Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117(8):1687–1696
-
(2011)
Cancer
, vol.117
, Issue.8
, pp. 1687-1696
-
-
Davies, M.A.1
Liu, P.2
McIntyre, S.3
Kim, K.B.4
Papadopoulos, N.5
Hwu, W.J.6
Hwu, P.7
Bedikian, A.8
-
5
-
-
84872361487
-
Dabrafenib and its potential for the treatment of metastatic melanoma
-
PID: 23251089, COI: 1:CAS:528:DC%2BC38XhvFSlu7vJ
-
Menzies AM, Long GV, Murali R (2012) Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther 6:391–405
-
(2012)
Drug Des Devel Ther
, vol.6
, pp. 391-405
-
-
Menzies, A.M.1
Long, G.V.2
Murali, R.3
-
6
-
-
84883559224
-
The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions
-
PID: 23845462
-
Murrell J, Board R (2013) The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions. Cancer Treat Rev 39(8):833–838
-
(2013)
Cancer Treat Rev
, vol.39
, Issue.8
, pp. 833-838
-
-
Murrell, J.1
Board, R.2
-
7
-
-
84910121299
-
Multidisciplinary approach to brain metastases from melanoma
-
Long GV, Margolin KA (2013) Multidisciplinary approach to brain metastases from melanoma. Am Soc Clin Oncol Educ Book 2013:393–398
-
(2013)
Am Soc Clin Oncol Educ Book
, vol.2013
, pp. 393-398
-
-
Long, G.V.1
Margolin, K.A.2
-
8
-
-
84855440693
-
Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM)
-
Kim KB, Flaherty KT, Chapman PB, Sosman JA, Ribas A, McArthur GA, Amaravadi RK, Lee RJ, Nolop KB, Puzanov I (2011) Pattern and outcome of disease progression in phase I study of vemurafenib in patients with metastatic melanoma (MM). J Clin Oncol 29(15):1628–1634
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
, pp. 1628-1634
-
-
Kim, K.B.1
Flaherty, K.T.2
Chapman, P.B.3
Sosman, J.A.4
Ribas, A.5
McArthur, G.A.6
Amaravadi, R.K.7
Lee, R.J.8
Nolop, K.B.9
Puzanov, I.10
-
9
-
-
84876074045
-
Treatment of metastatic malignant melanoma with vemurafenib during pregnancy
-
PID: 23401457
-
Maleka A, Enblad G, Sjors G, Lindqvist A, Ullenhag GJ (2013) Treatment of metastatic malignant melanoma with vemurafenib during pregnancy. J Clin Oncol 31(11):e192–e193
-
(2013)
J Clin Oncol
, vol.31
, Issue.11
, pp. e192-e193
-
-
Maleka, A.1
Enblad, G.2
Sjors, G.3
Lindqvist, A.4
Ullenhag, G.J.5
-
10
-
-
84871900504
-
Melanoma brain metastases and vemurafenib: Need for further investigation
-
PID: 23036672, COI: 1:CAS:528:DC%2BC3sXntlaqsQ%3D%3D
-
Rochet NM, Dronca RS, Kottschade LA, Chavan RN, Gorman B, Gilbertson JR, Markovic SN (2012) Melanoma brain metastases and vemurafenib: need for further investigation. Mayo Clin Proc 87(10):976–981
-
(2012)
Mayo Clin Proc
, vol.87
, Issue.10
, pp. 976-981
-
-
Rochet, N.M.1
Dronca, R.S.2
Kottschade, L.A.3
Chavan, R.N.4
Gorman, B.5
Gilbertson, J.R.6
Markovic, S.N.7
-
11
-
-
84861079916
-
Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): A case report
-
PID: 22594466
-
Simeone E, De Maio E, Sandomenico F, Fulciniti F, Lastoria S, Aprea P, Staibano S, Montesarchio V, Palmieri G, Mozzillo N, Ascierto PA (2012) Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF inhibitor): a case report. J Med Case Rep 6(1):131
-
(2012)
J Med Case Rep
, vol.6
, Issue.1
, pp. 131
-
-
Simeone, E.1
De Maio, E.2
Sandomenico, F.3
Fulciniti, F.4
Lastoria, S.5
Aprea, P.6
Staibano, S.7
Montesarchio, V.8
Palmieri, G.9
Mozzillo, N.10
Ascierto, P.A.11
-
12
-
-
84874949127
-
Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: A case report
-
PID: 23358426
-
Lee JM, Mehta UN, Dsouza LH, Guadagnolo BA, Sanders DL, Kim KB (2013) Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report. Melanoma Res 23(2):175–178
-
(2013)
Melanoma Res
, vol.23
, Issue.2
, pp. 175-178
-
-
Lee, J.M.1
Mehta, U.N.2
Dsouza, L.H.3
Guadagnolo, B.A.4
Sanders, D.L.5
Kim, K.B.6
-
13
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
PID: 22113612, COI: 1:CAS:528:DC%2BC3MXhsFWqtL%2FN
-
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480(7377):387–390
-
(2011)
Nature
, vol.480
, Issue.7377
, pp. 387-390
-
-
Poulikakos, P.I.1
Persaud, Y.2
Janakiraman, M.3
Kong, X.4
Ng, C.5
Moriceau, G.6
Shi, H.7
Atefi, M.8
Titz, B.9
Gabay, M.T.10
Salton, M.11
Dahlman, K.B.12
Tadi, M.13
Wargo, J.A.14
Flaherty, K.T.15
Kelley, M.C.16
Misteli, T.17
Chapman, P.B.18
Sosman, J.A.19
Graeber, T.G.20
Ribas, A.21
Lo, R.S.22
Rosen, N.23
Solit, D.B.24
more..
-
14
-
-
84859183431
-
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
-
PID: 22395615
-
Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS (2012) Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724
-
(2012)
Nat Commun
, vol.3
, pp. 724
-
-
Shi, H.1
Moriceau, G.2
Kong, X.3
Lee, M.K.4
Lee, H.5
Koya, R.C.6
Ng, C.7
Chodon, T.8
Scolyer, R.A.9
Dahlman, K.B.10
Sosman, J.A.11
Kefford, R.F.12
Long, G.V.13
Nelson, S.F.14
Ribas, A.15
Lo, R.S.16
-
15
-
-
49649118852
-
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
-
PID: 18559533, COI: 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
-
Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68(12):4853–4861
-
(2008)
Cancer Res
, vol.68
, Issue.12
, pp. 4853-4861
-
-
Montagut, C.1
Sharma, S.V.2
Shioda, T.3
McDermott, U.4
Ulman, M.5
Ulkus, L.E.6
Dias-Santagata, D.7
Stubbs, H.8
Lee, D.Y.9
Singh, A.10
Drew, L.11
Haber, D.A.12
Settleman, J.13
-
16
-
-
80051625929
-
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
-
PID: 21383288, COI: 1:CAS:528:DC%2BC3MXhtFCqtLfO
-
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29(22):3085–3096
-
(2011)
J Clin Oncol
, vol.29
, Issue.22
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
Davis, M.J.4
Sawyer, A.5
Pochanard, P.6
Kehoe, S.M.7
Johannessen, C.M.8
Macconaill, L.E.9
Hahn, W.C.10
Meyerson, M.11
Garraway, L.A.12
-
17
-
-
78650309875
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
-
PID: 21107320, COI: 1:CAS:528:DC%2BC3cXhsVOrsLvP
-
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468(7326):968–972
-
(2010)
Nature
, vol.468
, Issue.7326
, pp. 968-972
-
-
Johannessen, C.M.1
Boehm, J.S.2
Kim, S.Y.3
Thomas, S.R.4
Wardwell, L.5
Johnson, L.A.6
Emery, C.M.7
Stransky, N.8
Cogdill, A.P.9
Barretina, J.10
Caponigro, G.11
Hieronymus, H.12
Murray, R.R.13
Salehi-Ashtiani, K.14
Hill, D.E.15
Vidal, M.16
Zhao, J.J.17
Yang, X.18
Alkan, O.19
Kim, S.20
Harris, J.L.21
Wilson, C.J.22
Myer, V.E.23
Finan, P.M.24
Root, D.E.25
Roberts, T.M.26
Golub, T.27
Flaherty, K.T.28
Dummer, R.29
Weber, B.L.30
Sellers, W.R.31
Schlegel, R.32
Wargo, J.A.33
Hahn, W.C.34
Garraway, L.A.35
more..
-
18
-
-
78650008177
-
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K
-
PID: 21156289, COI: 1:CAS:528:DC%2BC3cXhsFGhsbjJ
-
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3 K. Cancer Cell 18(6):683–695
-
(2010)
Cancer Cell
, vol.18
, Issue.6
, pp. 683-695
-
-
Villanueva, J.1
Vultur, A.2
Lee, J.T.3
Somasundaram, R.4
Fukunaga-Kalabis, M.5
Cipolla, A.K.6
Wubbenhorst, B.7
Xu, X.8
Gimotty, P.A.9
Kee, D.10
Santiago-Walker, A.E.11
Letrero, R.12
D’Andrea, K.13
Pushparajan, A.14
Hayden, J.E.15
Brown, K.D.16
Laquerre, S.17
McArthur, G.A.18
Sosman, J.A.19
Nathanson, K.L.20
Herlyn, M.21
more..
-
19
-
-
77956045447
-
Melanoma–an unlikely poster child for personalized cancer therapy
-
COI: 1:CAS:528:DC%2BC3cXhtVyksbvL
-
Smalley KS, Sondak VK (2010) Melanoma–an unlikely poster child for personalized cancer therapy. Engl J Med 363(9):876–878
-
(2010)
Engl J Med
, vol.363
, Issue.9
, pp. 876-878
-
-
Smalley, K.S.1
Sondak, V.K.2
-
20
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
PID: 21107323, COI: 1:CAS:528:DC%2BC3cXhsVOrsbjI
-
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468(7326):973–977
-
(2010)
Nature
, vol.468
, Issue.7326
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
Kong, X.4
Koya, R.C.5
Lee, H.6
Chen, Z.7
Lee, M.K.8
Attar, N.9
Sazegar, H.10
Chodon, T.11
Nelson, S.F.12
McArthur, G.13
Sosman, J.A.14
Ribas, A.15
Lo, R.S.16
-
21
-
-
84962718929
-
-
Meier F, Forschner A, Klumpp B, Flaherty KT, Honegger JB, Witte M, Bornemann A, Dummer R, Bauer J, Tabatabai G, Weide B, Eigentler TK, Schadendorf D, Quintanilla-Fend L, Niessner H, Garbe C (2013) Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases Cancer Med 2(1):76–85
-
(2013)
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases Cancer Med
, vol.2
, Issue.1
, pp. 76-85
-
-
Meier, F.1
Forschner, A.2
Klumpp, B.3
Flaherty, K.T.4
Honegger, J.B.5
Witte, M.6
Bornemann, A.7
Dummer, R.8
Bauer, J.9
Tabatabai, G.10
Weide, B.11
Eigentler, T.K.12
Schadendorf, D.13
Quintanilla-Fend, L.14
Niessner, H.15
Garbe, C.16
-
22
-
-
84874442053
-
Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: Implications for the treatment of melanoma brain metastases
-
PID: 23249624, COI: 1:CAS:528:DC%2BC3sXjvVaju7Y%3D
-
Mittapalli RK, Vaidhyanathan S, Dudek AZ, Elmquist WF (2013) Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases. J Pharmacol Exp Ther 344(3):655–664
-
(2013)
J Pharmacol Exp Ther
, vol.344
, Issue.3
, pp. 655-664
-
-
Mittapalli, R.K.1
Vaidhyanathan, S.2
Dudek, A.Z.3
Elmquist, W.F.4
-
23
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial
-
PID: 22608338, COI: 1:CAS:528:DC%2BC38Xnt1Kmtbo%3D
-
Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901
-
(2012)
Lancet
, vol.379
, Issue.9829
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
Kim, K.B.4
Arkenau, T.H.5
Brown, M.P.6
Hamid, O.7
Infante, J.R.8
Millward, M.9
Pavlick, A.C.10
O’Day, S.J.11
Blackman, S.C.12
Curtis, C.M.13
Lebowitz, P.14
Ma, B.15
Ouellet, D.16
Kefford, R.F.17
-
24
-
-
84857127841
-
The blood-brain barrier: Its influence in the treatment of brain tumors metastases
-
PID: 22229251, COI: 1:CAS:528:DC%2BC38XktFWisbk%3D
-
Fortin D (2012) The blood-brain barrier: its influence in the treatment of brain tumors metastases. Curr Cancer Drug Targets 12(3):247–259
-
(2012)
Curr Cancer Drug Targets
, vol.12
, Issue.3
, pp. 247-259
-
-
Fortin, D.1
-
25
-
-
84879422839
-
Vemurafenib and radiation therapy in melanoma brain metastases
-
PID: 23579338, COI: 1:CAS:528:DC%2BC3sXpvFaktro%3D
-
Narayana A, Mathew M, Tam M, Kannan R, Madden KM, Golfinos JG, Parker EC, Ott PA, Pavlick AC (2013) Vemurafenib and radiation therapy in melanoma brain metastases. J Neurooncol 113(3):411–416
-
(2013)
J Neurooncol
, vol.113
, Issue.3
, pp. 411-416
-
-
Narayana, A.1
Mathew, M.2
Tam, M.3
Kannan, R.4
Madden, K.M.5
Golfinos, J.G.6
Parker, E.C.7
Ott, P.A.8
Pavlick, A.C.9
-
26
-
-
84862492216
-
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: Vemurafenib (PLX4032)
-
PID: 22454535, COI: 1:CAS:528:DC%2BC38XhtVOktbjE
-
Mittapalli RK, Vaidhyanathan S, Sane R, Elmquist WF (2012) Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032). J Pharmacol Exp Ther 342(1):33–40
-
(2012)
J Pharmacol Exp Ther
, vol.342
, Issue.1
, pp. 33-40
-
-
Mittapalli, R.K.1
Vaidhyanathan, S.2
Sane, R.3
Elmquist, W.F.4
-
27
-
-
84868556980
-
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
-
PID: 23020847, COI: 1:CAS:528:DC%2BC38XhsVamt7bL
-
Durmus S, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2012) Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Mol Pharm 9(11):3236–3245
-
(2012)
Mol Pharm
, vol.9
, Issue.11
, pp. 3236-3245
-
-
Durmus, S.1
Sparidans, R.W.2
Wagenaar, E.3
Beijnen, J.H.4
Schinkel, A.H.5
-
28
-
-
84903522581
-
Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets)
-
Harding JJ, Catalanotti F, Yaqubie A, McDermott GC, Kersellius R, Merghoub T (2013) Vemurafenib (VEM) in patients (pts) with BRAF-mutant melanoma and brain metastases (mets). J Clin Oncol 31:9060
-
(2013)
J Clin Oncol
, vol.31
, pp. 9060
-
-
Harding, J.J.1
Catalanotti, F.2
Yaqubie, A.3
McDermott, G.C.4
Kersellius, R.5
Merghoub, T.6
-
29
-
-
84904060551
-
Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases
-
Dzienis MR, Atkinson VG (2014).Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases. Melanoma Res 24(4):349–353
-
(2014)
Melanoma Res
, vol.24
, Issue.4
, pp. 349-353
-
-
Dzienis, M.R.1
Atkinson, V.G.2
-
30
-
-
84893661769
-
Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
-
PID: 24295639, COI: 1:CAS:528:DC%2BC3sXhvV2gtbbP
-
Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50(3):611–621
-
(2014)
Eur J Cancer
, vol.50
, Issue.3
, pp. 611-621
-
-
Dummer, R.1
Goldinger, S.M.2
Turtschi, C.P.3
Eggmann, N.B.4
Michielin, O.5
Mitchell, L.6
Veronese, L.7
Hilfiker, P.R.8
Felderer, L.9
Rinderknecht, J.D.10
-
31
-
-
84901272172
-
Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?
-
PID: 24721778
-
Baroudjian B, Boussemart L, Routier E, Dreno B, Tao Y, Deutsch E, Blanchard P, Dhermain F, Vilcot L, Vagner S, Eggermont A, Mateus C, Robert C (2014) Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? Eur J Dermatol 24(2):265–267
-
(2014)
Eur J Dermatol
, vol.24
, Issue.2
, pp. 265-267
-
-
Baroudjian, B.1
Boussemart, L.2
Routier, E.3
Dreno, B.4
Tao, Y.5
Deutsch, E.6
Blanchard, P.7
Dhermain, F.8
Vilcot, L.9
Vagner, S.10
Eggermont, A.11
Mateus, C.12
Robert, C.13
-
32
-
-
84893248463
-
Severe radiotherapy-induced extracutaneous toxicity under vemurafenib
-
PID: 24192487
-
Peuvrel L, Ruellan AL, Thillays F, Quereux G, Brocard A, Saint-Jean M, Aumont M, Drouet F, Dreno B (2013) Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. Eur J Dermatol 23(6):879–881
-
(2013)
Eur J Dermatol
, vol.23
, Issue.6
, pp. 879-881
-
-
Peuvrel, L.1
Ruellan, A.L.2
Thillays, F.3
Quereux, G.4
Brocard, A.5
Saint-Jean, M.6
Aumont, M.7
Drouet, F.8
Dreno, B.9
-
33
-
-
84868120907
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): A multicentre, open-label, phase 2 trial
-
PID: 23051966, COI: 1:CAS:528:DC%2BC38Xhs1WqurzP
-
Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095
-
(2012)
Lancet Oncol
, vol.13
, Issue.11
, pp. 1087-1095
-
-
Long, G.V.1
Trefzer, U.2
Davies, M.A.3
Kefford, R.F.4
Ascierto, P.A.5
Chapman, P.B.6
Puzanov, I.7
Hauschild, A.8
Robert, C.9
Algazi, A.10
Mortier, L.11
Tawbi, H.12
Wilhelm, T.13
Zimmer, L.14
Switzky, J.15
Swann, S.16
Martin, A.M.17
Guckert, M.18
Goodman, V.19
Streit, M.20
Kirkwood, J.M.21
Schadendorf, D.22
more..
|